Releases Details
Result of AGM
Released : November 02, 2020 15:52
Result of AGM
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in
###
Contacts:
|
MaxCyte Inc. Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer
|
+1 301-944-1660 |
|
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking Rupert Dearden
|
+44 (0)20 7886 2500 |
|
Joint Corporate Broker Numis Securities Limited James Black Duncan Monteith
|
+44 (0)20 7260 1000 |
|
Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh
-------------------------------------------------------------- |
+44 (0)203 709 5700 maxcyte@consilium-comms.com |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
